Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis
- PMID: 15193292
- DOI: 10.1016/j.nbd.2004.03.005
Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis
Abstract
Infantile neuronal ceroid lipofuscinosis (INCL) is the earliest onset form of a class of inherited neurodegenerative disease called Batten disease. INCL is caused by a deficiency in the lysosomal enzyme palmitoyl protein thioesterase-1 (PPT1). Autofluorescent storage material accumulates in virtually all tissues in INCL patients, including the brain, and leads to widespread neuronal loss and cortical atrophy. To determine the efficacy of viral-mediated gene therapy, we injected a recombinant adeno-associated virus 2 vector encoding human PPT1 (rAAV-PPT1) intracranially (I.C.) into a murine model of INCL. INCL mice given four I.C. injections of rAAV-PPT1 as newborns exhibited PPT1 activity near the injection sites and decreased secondary elevations of another lysosomal enzyme. In addition, storage material was decreased in cortical, hippocampal, and cerebellar neurons, and brain weights and cortical thicknesses were increased. These data demonstrate that an adeno-associated virus 2 (AAV2)-mediated gene therapy approach may provide some therapeutic benefit for INCL.
Similar articles
-
AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis.Mol Ther. 2005 Sep;12(3):413-21. doi: 10.1016/j.ymthe.2005.04.018. Mol Ther. 2005. PMID: 15979943
-
Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis.Neurobiol Dis. 2004 Jul;16(2):346-59. doi: 10.1016/j.nbd.2004.02.010. Neurobiol Dis. 2004. PMID: 15193291
-
Synergistic effects of treating the spinal cord and brain in CLN1 disease.Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5920-E5929. doi: 10.1073/pnas.1701832114. Epub 2017 Jul 3. Proc Natl Acad Sci U S A. 2017. PMID: 28673981 Free PMC article.
-
Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).Biochim Biophys Acta. 2013 Nov;1832(11):1906-9. doi: 10.1016/j.bbadis.2013.05.026. Epub 2013 Jun 6. Biochim Biophys Acta. 2013. PMID: 23747979 Free PMC article. Review.
-
Pathogenesis of brain dysfunction in Batten disease.Am J Med Genet. 1995 Jun 5;57(2):196-203. doi: 10.1002/ajmg.1320570218. Am J Med Genet. 1995. PMID: 7668330 Review.
Cited by
-
Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep.J Clin Invest. 2022 Oct 17;132(20):e163107. doi: 10.1172/JCI163107. J Clin Invest. 2022. PMID: 36040802 Free PMC article.
-
Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.J Neurosci. 2006 Feb 1;26(5):1334-42. doi: 10.1523/JNEUROSCI.2676-05.2006. J Neurosci. 2006. PMID: 16452657 Free PMC article.
-
Genetically Corrected iPSC-Derived Neural Stem Cell Grafts Deliver Enzyme Replacement to Affect CNS Disease in Sanfilippo B Mice.Mol Ther Methods Clin Dev. 2018 Jul 23;10:113-127. doi: 10.1016/j.omtm.2018.06.005. eCollection 2018 Sep 21. Mol Ther Methods Clin Dev. 2018. PMID: 30101150 Free PMC article.
-
Effects of chronic cannabidiol in a mouse model of naturally occurring neuroinflammation, neurodegeneration, and spontaneous seizures.Sci Rep. 2022 Jul 4;12(1):11286. doi: 10.1038/s41598-022-15134-5. Sci Rep. 2022. PMID: 35789177 Free PMC article.
-
Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease.Hum Mol Genet. 2009 Nov 1;18(21):4066-80. doi: 10.1093/hmg/ddp355. Epub 2009 Jul 29. Hum Mol Genet. 2009. PMID: 19640925 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
